Page 17 - Lupin

Lower tax rate boosts Lupin's Q1 net by 68%

Shares in Lupin fell as much as 6% to a one-month low of 1,598 rupees following the results, before closing down 5%

Lupin dips on weak Q1 operating margin

The stock dipped 5% to Rs 1,607, falling 7% from intra-day high of Rs 1,730 on the BSE.

Lupin expands Japan business with Rs 1,000 crore buy

Japan accounts for about 10% of Lupin's revenue and is its third biggest market after the US and India

Lupin to buy 21 products of Japan's Shionogi for Rs 1,000 crore

With 21 new brands, Kyowa will rank sixth amongst generic companies in the country

Competition Commission slaps Rs 73 cr fine on Lupin

CCI's order has come on a complaint filed by Maruti & Company

Lupin launches generic oral contraceptive tablets in US

Shares of Lupin closed at Rs 1,713.60 per scrip on BSE, up 1.37%

USFDA clears Lupin's Goa plant, closes July 2015 inspection

The Goa plant accounts for 50% of Lupin's US sales and adverse observations from FDA resulted in delayed product approvals for the company

Lupin surges on receiving EIR from USFDA for Goa facility

The stock moved higher by 9% to Rs 1,698 on the NSE.

Lupin records sharpest single day gain in three months

The stock ended higher by 4.4% to Rs 1,543 on the BSE, recorded its sharpest single day gain since March 30, 2016.

Lupin gets USFDA nod for fungal infection drug

Mumbai based Lupin produces and develops a wide range of branded & generic formulations, biotechnology products and APIs globally

Lupin shares fall 2% on product recall in US

Company's US arm Lupin Pharmaceuticals Inc is initiating the recall

Lupin recalls over 54,000 vials of anti-bacterial injection in US

Anti-bacterial injection Ceftriaxone are being recalled due to violation of current good manufacturing norms

Lupin gets final USFDA nod for fungal treatment drug

Lupin further said that the company shall commence promoting the products in the US shortly

Lupin eyes 25-30 product launches in US this fiscal

Overall, between Lupin and Gavis combined, over 160 products filings are pending for approval with USFDA

FDA clears Lupin's Aurangabad, Mandideep plants

Earlier, both the plants had received adverse observations from the US drug regulator

Lupin tanks 9% on FDA concerns

In March, Lupin received nine adverse observations from US drug regulator at its Goa plant and the company expects resolution in the next 3-6 months

Lupin dips on USFDA concerns about Goa plant

The stock dipped almost 8% to Rs 1,525 on the BSE in early morning trade on the BSE.

Expect business to grow 20% in FY17: Vinita Gupta

Interview with CEO, Lupin

Lupin Q4 net surges 47.5% to Rs 807 cr

Total revenue grew 34% to Rs 4,091 cr

Lupin ends the year on a strong note

Diabetics products boost US growth; India, Japan, others add to Street beating performance